Medison Creates Significant Change at Knight Therapeutics
Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), today issued the following statement from Medison CEO Meir Jakobsohn on Knight's 2019 Annual Meeting of Shareholders:
Our campaign created unanimous consent that an immediate change is required at Knight and also a collective demand from shareholders that Knight's leadership create near term value and increase the share price.
Our campaign "rocked the boat" and made Knight's leadership commit to implementing required changes that can increase the share price.
Medison nominee, Kevin Cameron, together with new independent nominee Michael Tremblay, have been elected to Knight Board of Directors and will assist in remedying governance deficiencies and conflicts of interest exposed by Medison's campaign.
I would like to note that I decided to withdraw my nomination for the board, as I believe I can be more effective operating from the outside as an active shareholder.
We respect the shareholder vote not to adopt the Diamond Strategy, and Medison pledges to pursue it independent of Knight.
To all our fellow Knight shareholders, Medison intends to maintain an open dialogue with you and will continue to highlight key findings and perspectives as appropriate.
I personally thank each shareholder on your engagement in open discussions with us, on being open and transparent even when we had different views on some matters, and on being able to disregard misinformation and distractions and focus on the real issues at hand, which we face together as shareholders of Knight.
Medison will maintain its website www.NewDayForKnight.com and shareholders are encouraged to visit it for updates.
About Medison
Medison is one of the world's largest commercial partners of leading global biotech companies. Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in Israeli and selected ROW markets. Over the years, Medison has become the partner of choice for biotech companies that produce highly innovative, cutting edge therapeutics for commercialization in the Israeli market and is currently the second largest pharmaceutical company in Israel, with over CAD 250 million in revenues annually and over 270 employees. Medison runs a corporate venture arm with a dedicated research and evaluation team boasting deep scientific and commercial backgrounds. Medison also operates a scouting program to cater to its partners and is an active investor in life science projects around drug development and digital health.
News published on and distributed by:
